Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774219 | 0.82 | PANK3 (0.58) | NAMPTHRH3 | |
| SCHEMBL4771050 | 0.81 | CYP3A4 (0.56) | NAMPTHRH3NPC1TP53HTT | |
| SCHEMBL4765583 | 0.81 | HRH3 (0.43) | NAMPTHRH3KDM4EALDH1A1 | |
| SCHEMBL4767666 | 0.80 | CYP3A4 (0.58) | NAMPTHRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4770989 | 0.80 | SMN1; SMN2 (0.71) | HRH3NPC1TP53HTTRAB9A | |
| SCHEMBL4772344 | 0.80 | MAPT (0.58) | NAMPTHRH3HTTSMN1; SMN2MAPT | |
| SCHEMBL4767933 | 0.79 | RAB9A (0.52) | NAMPTHRH3NPC1TP53RAB9A | |
| SCHEMBL4765684 | 0.79 | NAMPT (0.47) | NAMPTHRH3NPC1TP53HTT | |
| SCHEMBL3101154 | 0.78 | HRH3 (0.65) | HRH3 | |
| SCHEMBL4765431 | 0.78 | HRH3 (0.58) | HRH3NPC1TP53HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | NAMPT 2325/4885HRH3 1/4885NPC1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.